

Marica Eoli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9452882/marica-eoli-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

6,519
citations

32
h-index

79
g-index

136
ext. papers

8,026
ext. citations

5.8
avg, IF

4.54
L-index

#	Paper	IF	Citations
126	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
125	Clonal evolution of glioblastoma under therapy. <i>Nature Genetics</i> , 2016 , 48, 768-76	36.3	390
124	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015 , 21, 3307-17	12.9	176
123	Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. <i>Clinical Cancer Research</i> , 2007 , 13, 2606-13	12.9	123
122	Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2003 , 62, 297-303	4.8	121
121	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 110-119	21.7	116
120	Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. <i>Brain</i> , 2014 , 137, 1907-20	11.2	107
119	Is fluorescein-guided technique able to help in resection of high-grade gliomas?. <i>Neurosurgical Focus</i> , 2014 , 36, E5	4.2	106
118	Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. <i>Acta Neurochirurgica</i> , 2013 , 155, 1277-86	3	100
117	Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). <i>Clinical Cancer Research</i> , 2018 , 24, 52-61	12.9	96
116	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. <i>American Journal of Human Genetics</i> , 2018 , 102, 69-87	11	93
115	The molecular landscape of glioma in patients with Neurofibromatosis 1. <i>Nature Medicine</i> , 2019 , 25, 176-183	51.7	88
114	Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. <i>Neuromuscular Disorders</i> , 2000 , 10, 391-7	2.9	86
113	NI-26 * COMPARATIVE ANALYSIS OF THE RANO AND MACDONADO CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.. <i>Neuro-Oncology</i> , 2014 , 16, v143-v144	1	78
112	High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. <i>Molecular Cancer Research</i> , 2009 , 7, 665-77	6.6	78
111	NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. <i>Oncotarget</i> , 2012 , 3, 723-34	3.4	69
110	Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. <i>European Neurology</i> , 1994 , 34, 199-203	2.1	68

109	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 684-693	1	62
108	CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. <i>Journal of Neuro-Oncology</i> , 2004 , 67, 305-17	4.8	60
107	Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2004 , 66, 203-8	4.8	54
106	Fluorescein-guided surgery for malignant gliomas: a review. <i>Neurosurgical Review</i> , 2014 , 37, 547-57	3.9	53
105	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1304-12	1	53
104	CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. <i>Journal of Neuro-Oncology</i> , 2005 , 74, 287-93	4.8	47
103	Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. <i>Human Mutation</i> , 2020 , 41, 299-315	4.7	47
102	Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. <i>Neuroscience Letters</i> , 2004 , 370, 180-5	3.3	45
101	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. <i>Oncolmmunology</i> , 2013 , 2, e23401	7.2	42
100	Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. <i>European Neurology</i> , 1989 , 29, 10-4	2.1	41
99	Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006 , 119, 84-90	7.5	39
98	Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005 , 72, 125-31	4.8	36
97	Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015 , 125, 359-67	4.8	34
96	Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide. <i>Oncolmmunology</i> , 2018 , 7, e1412901	7.2	34
95	A double blind study on azathioprine efficacy in multiple sclerosis: final report. <i>Journal of Neurology</i> , 1993 , 240, 295-8	5.5	33
94	Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. <i>Neurosurgical Review</i> , 2016 , 39, 37-45; discussion 45-6	3.9	32
93	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. <i>Journal of Neuro-Oncology</i> , 2008 , 88, 105-13	4.8	31
92	Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 279-88	4.8	29

91	Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2008 , 87, 143-51	4.8	29
90	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. <i>Annals of Neurology</i> , 2002 , 52, 842-5	9.4	29
89	VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 499-504	4.8	26
88	Headache in brain tumours: a symptom to reappraise critically. <i>Neurological Sciences</i> , 2004 , 25 Suppl 3, S143-7	3.5	24
87	FABP4 is a candidate marker of cerebellar liponeurocytomas. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 513-28	4.8	23
86	Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. <i>Neurological Sciences</i> , 2002 , 23, 219-24	3.5	23
85	Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2005 , 74, 87-9	4.8	23
84	Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. <i>Italian Journal of Neurological Sciences</i> , 1999 , 20, 43-8		23
83	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 115-20	3.5	22
82	126 novel mutations in Italian patients with neurofibromatosis type 1. <i>Molecular Genetics & Genomic Medicine</i> , 2015 , 3, 513-25	2.3	22
81	Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. <i>PLoS ONE</i> , 2013 , 8, e74345	3.7	21
80	Management of epilepsy in brain tumors. <i>Neurological Sciences</i> , 2019 , 40, 2217-2234	3.5	20
79	Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2009 , 95, 61-64	4.8	20
78	Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990 , 53, 554-7	5.5	20
77	DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence. <i>Oncologist</i> , 2011 , 16, 1440-50	5.7	19
76	Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study. <i>Journal of Neuro-Oncology</i> , 2005 , 71, 271-6	4.8	19
75	Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. <i>Cancer Letters</i> , 1999 , 146, 169-72	9.9	19
74	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020 , 22, 1614-1624	1	18

73	Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. <i>Journal of Neuro-Oncology</i> , 2001 , 54, 39-47	4.8	18
72	Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment. <i>Italian Journal of Neurological Sciences</i> , 1994 , 15, 333-40		18
71	Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2009 , 94, 57-62	4.8	17
70	Immunological monitoring of azathioprine treatment in multiple sclerosis patients. <i>Journal of Neurology</i> , 1997 , 244, 167-74	5.5	17
69	The myelin basic protein gene is not a major susceptibility locus for multiple sclerosis in Italian patients. <i>Journal of Neurology</i> , 1994 , 241, 615-9	5.5	17
68	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. <i>European Journal of Neurology</i> , 2019 , 26, 639-650	6	17
67	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. <i>Neuro-Oncology</i> , 2021 , 23, 264-276	1	17
66	Local drug delivery in recurrent malignant gliomas. <i>Neurological Sciences</i> , 2005 , 26 Suppl 1, S37-9	3.5	16
65	Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. <i>Italian Journal of Neurological Sciences</i> , 1998 , 19, 32-6		15
64	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. <i>Journal of Neuro-Oncology</i> , 2007 , 82, 273-9	4.8	15
63	Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005 , 75, 215-20	4.8	15
62	Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity. <i>Journal of Neurology</i> , 1993 , 240, 79-82	5.5	14
61	Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. <i>PLoS ONE</i> , 2014 , 9, e90535	3.7	14
60	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 205-210	4.8	13
59	Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 178-9	3.5	13
58	A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients. <i>PLoS ONE</i> , 2014 , 9, e114713	3.7	13
57	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019 , 21, 1263-1272	1	12
56	Analysis of HLA-class II DQA1, DQB1, DRB1 and DPB1 in Italian multiple sclerosis patients. <i>International Journal of Immunogenetics</i> , 1995 , 22, 171-8		12

55	CSF T-cell subsets in multiple sclerosis: relationship to cerebrospinal fluid myelin basic protein and clinical activity. <i>Journal of Neurology</i> , 1989 , 236, 336-9	5.5	12
54	Evidence of linkage between susceptibility to multiple sclerosis and HLA-class II loci in Italian multiplex families. <i>European Journal of Human Genetics</i> , 1995 , 3, 303-11	5.3	12
53	Genetic signature of adult gliomas and correlation with MRI features. <i>Expert Review of Molecular Diagnostics</i> , 2009 , 9, 709-20	3.8	11
52	No linkage between multiple sclerosis and the T cell receptor alpha chain locus. <i>Journal of the Neurological Sciences</i> , 1994 , 124, 32-7	3.2	11
51	Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. <i>Molecular Cancer</i> , 2013 , 12, 160	42.1	10
50	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2023-2023	2.2	10
49	LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410. <i>Neuro-Oncology</i> , 2017 , 19, vi316-vi316	1	9
48	Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report. <i>Neurological Sciences</i> , 2002 , 23, 257-8	3.5	9
47	Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. <i>Journal of Neuro-Oncology</i> , 2000 , 49, 71-5	4.8	9
46	Embryonal tumors in the adult population: implications in therapeutic planning. <i>Neurological Sciences</i> , 2000 , 21, 23-30	3.5	9
45	Racemose neurocysticercosis after chronic meningitis: effect of medical treatment. <i>Clinical Neurology and Neurosurgery</i> , 1995 , 97, 50-4	2	9
44	HLA antigens in Italian multiple sclerosis patients. <i>Italian Journal of Neurological Sciences</i> , 1991 , 12, 81-6		9
43	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017 , 8, 55575-55581	3.3	9
42	ABCC3 Expressed by CD56 CD16 NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	9
41	Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort. <i>Cancers</i> , 2019 , 11,	6.6	9
40	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz022	0.9	8
39	Meningo-cortical calcifying angiomatosis and celiac disease. <i>Clinical Neurology and Neurosurgery</i> , 1998 , 100, 209-15	2	8
38	Depatuzumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). <i>Cancers</i> , 2021 , 13,	6.6	8

37	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 831-842	7.4	8
36	Biopsy-proven primary angiitis of the central nervous system mimicking leukodystrophy: A case report and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2019 , 64, 42-44	2.2	7
35	Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: Rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients. <i>Genes</i> , 2019 , 10,	4.2	7
34	HLA and multiple sclerosis in Italy: a review of the literature. <i>Journal of Neurology</i> , 1990 , 237, 441-4	5.5	7
33	Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
32	Parallel fluctuations of psychiatric and neurological symptoms in a patient with multiple sclerosis and bipolar affective disorder. <i>Italian Journal of Neurological Sciences</i> , 1995 , 16, 551-3		6
31	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdz051	0.9	6
30	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. <i>Clinical Cancer Research</i> , 2020 , 26, 4478-4484 ^{12.9}		5
29	Short-term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment. <i>Italian Journal of Neurological Sciences</i> , 1992 , 13, 107-12		5
28	Molecular markers of gliomas: a clinical approach. <i>Neurological Research</i> , 2006 , 28, 538-41	2.7	4
27	Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. <i>Neurological Sciences</i> , 2003 , 24, 272	3.5	4
26	Phenotype analysis of unstimulated lymphocytes and anti-CD3-stimulated proliferating T-cells from cerebrospinal fluid and peripheral blood in patients with multiple sclerosis and other neurological diseases. <i>International Journal of Neuroscience</i> , 1993 , 73, 277-85	2	4
25	Neurological malignancies in neurofibromatosis type 1. <i>Current Opinion in Oncology</i> , 2019 , 31, 554-561	4.2	4
24	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). <i>European Journal of Cancer</i> , 2021 , 155, 179-190 ^{7.5}		4
23	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2017 , 7, 592-597	3.6	3
22	The noncoding RNA AK127244 in 2p16.3 locus: A new susceptibility region for neuropsychiatric disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018 , 177, 557-562	3.5	3
21	Role of physical training on immune function: preliminary data. <i>International Journal of Neuroscience</i> , 1990 , 51, 249-52	2	3
20	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2085-TPS2085	2.2	3

19	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2047-2047	2.2	3
18	Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches.. <i>Cancers</i> , 2021 , 13,	6.6	3
17	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2045-2045	2.2	2
16	Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. <i>Journal of Neurosurgery</i> , 2003 , 98, 935-6; author reply 936	3.2	2
15	Simultaneous Detection of , , , and Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. <i>Genes</i> , 2020 , 11,	4.2	1
14	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. <i>Neurological Sciences</i> , 2020 , 41, 2111-2120	3.5	1
13	Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease). <i>Neurological Sciences</i> , 2012 , 33, 1429-33	3.5	1
12	Cryoglobulinemic neuropathy: case report. <i>Italian Journal of Neurological Sciences</i> , 1988 , 9, 391-5		1
11	Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2087-2087	2.2	1
10	Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma. <i>Frontiers in Oncology</i> , 2021 , 11, 747690	5.3	1
9	Apparent diffusion coefficient (ADC) decrease to predict longer survival in glioblastoma patients treated by dendritic cell immunotherapy plus standard of care.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2065-2065	2.2	0
8	The role of the neurologist. <i>Neurological Sciences</i> , 2005 , 26 Suppl 1, S46-8	3.5	
7	Tetanus toxoid pre-conditioning in recurrent glioblastoma treated with dendritic cell immunotherapy is associated to CD8+ T cell response.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14053-e14053	2.2	3
6	Neurofibromatosis Type 1 and Type 2 2015 , 349-354		
5	Can Diffusion and Perfusion Weighted Imaging predict 1p/19q codeled lower grade gliomas?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2056-2056	2.2	
4	Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13003-e13003	2.2	
3	Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2039-2039	2.2	
2	Molecular Markers of Gliomas 2009 , 157-177		

- 1 Tumori cerebrali **2009**, 297-314